Cusabio Polyclonal Antibodies
Phospho-Cdc25b (Ser149) Antibody | CSB-PA905252
- SKU:
- CSB-PA905252
- Availability:
- 3 to 7 Working Days
- Size:
- 100ul
Description
Phospho-Cdc25b (Ser149) Antibody | CSB-PA905252 | Cusabio
Phospho-Cdc25b (Ser149) Antibody is Available at Gentaur Genprice with the fastest delivery.
Online Order Payment is possible or send quotation to info@gentaur.com.
Product Type: Polyclonal Antibody
Target Names: Cdc25b
Aliases: CDC25B
Background:
Cdc25B is a member of the CDC25 family of phosphatases. CDC25B activates the cyclin dependent kinase CDC2 by removing two phosphate groups and it is required for entry into mitosis. CDC25B shuttles between the nucleus and the cytoplasm due to nuclear localization and nuclear export signals. The protein is nuclear in the M and G1 phases of the cell cycle and moves to the cytoplasm during S and G2. CDC25B has oncogenic properties, although its role in tumor formation has not been determined. Multiple transcript variants for this gene exist.
Li G, et al. (2010) Retrovirology.7:59.
Wang Z, et al. (2010) BMC Cancer.10:233.
Lucci MA, et al. (2010) Cell Oncol.32 (5-6) :361-72.
Isotype: IgG
Conjugate: Non-conjugated
Clonality: Polyclonal
Uniport ID: Q9DBN8
Host Species: Rabbit
Species Reactivity: Mouse, Rat
Immunogen: Peptide sequence around phosphorylation site of Serine 149 (F-R-S (p) -L-P) derived from Mouse Cdc25B.
Immunogen Species: Mouse
Applications: ELISA, WB
Tested Applications: ELISA, WB;WB:1:500-1:1000
Purification Method: Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Dilution Ratio1: ELISA:1:2000-1:10000
Dilution Ratio2: WB:1:500-1:1000
Dilution Ratio3:
Dilution Ratio4:
Dilution Ratio5:
Dilution Ratio6:
Buffer: Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form: liquid
Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Initial Research Areas: Others
Research Areas: Others